Загрузка...
Triheptanoin: First Approval
Triheptanoin (Dojolvi™), a synthetic medium-chain triglyceride, is being developed by Ultragenyx Pharmaceutical as a pharmaceutical-grade anaplerotic compound for use in the treatment of inherited metabolic disorders. In June 2020, triheptanoin received its first regulatory approval, in the USA, for...
Сохранить в:
| Опубликовано в: : | Drugs |
|---|---|
| Главный автор: | |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer International Publishing
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7575481/ https://ncbi.nlm.nih.gov/pubmed/32897506 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01399-5 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|